https://www.selleckchem.com/pr....oducts/favipiravir-t
ich may potentially help clinicians to make clinical decisions and follow-up strategies for patients with CDC. Larger studies are needed to better understand this aggressive tumor. This study intended to retrospectively analyze the data of patients with primary retroperitoneal liposarcoma in a single Asian large-volume sarcoma center and to establish nomograms focused on PRLPS for predicting progression-free survival (PFS) and overall survival (OS). A total of 211 patients treated surgically for primary, non-metastatic retrope
Like
Comment
Share
